Oliver Robinson, a 34-year-old man who struggled with severe mental health issues, tragically took his own life in November 2023. Following an inquest into his death, there is a growing outcry for stricter controls over private cannabis clinics in the UK, particularly regarding the prescription of medicinal cannabis to individuals with serious mental health conditions. The findings from the inquest have prompted his family to advocate for significant changes in how these clinics operate.
A History of Mental Health Struggles
Oliver Robinson’s journey through mental health care began after a series of personal and professional setbacks, including the collapse of his property development business and a troubled relationship. From 2019 to 2022, he sought treatment at the Priory, a private mental health facility, where he was diagnosed with recurrent depressive disorder. Despite undergoing various forms of therapy, Oliver felt that conventional treatments had failed him.
In May 2022, after leaving the Priory, he turned to Curaleaf Clinic, a private cannabis provider, in search of relief from his persistent depression. Initially, he believed that medicinal cannabis offered him a pathway to emotional stability, but his family asserts that this treatment ultimately exacerbated his condition.
Inquest Findings Raise Serious Concerns
The inquest revealed that Robinson’s prescription for medicinal cannabis likely played a role in his death. Coroner Catherine McKenna concluded that the cannabis acted as a barrier to appropriate psychiatric and addiction care. This ruling marks a significant moment in the discourse surrounding the prescription of medicinal cannabis, with concerns mounting over its safety and efficacy, especially for those with complex mental health needs.
Dr Pavan Chahl, a psychiatrist who provided testimony during the inquest, stated that the existing guidelines of the British National Formulary clearly recommend against prescribing cannabis to individuals with a history of severe psychiatric disorders. He emphasised the lack of evidence supporting cannabis as an effective treatment for depression and highlighted the potential for it to worsen symptoms in vulnerable patients.
Advocating for “Oliver’s Law”
In response to these findings, Oliver’s brother, Alexander Robinson, has initiated a campaign aimed at reforming the regulatory landscape for private cannabis clinics. This campaign, dubbed “Oliver’s Law,” calls for a series of measures, including:
– **A ban on prescribing cannabis to patients with serious mental illnesses.**
– **Mandatory consultations with NHS mental health teams before prescriptions.**
– **Face-to-face assessments for complex cases rather than reliance on video consultations.**
– **Enhanced oversight from the Care Quality Commission (CQC), including routine audits and the publication of prescribing data.**
– **Mandatory reporting of serious adverse effects and clearer sanctions from the General Medical Council (GMC) for unsafe prescribing practices.**
Alexander Robinson expressed his deep concern that without significant changes, others in a similar situation to his brother could face dire consequences. “If things do not change he is not going to be the last,” he stated, advocating for a more rigorous evaluation of the potential risks involved in prescribing cannabis to vulnerable populations.
The Regulatory Landscape of Medicinal Cannabis in the UK
Since the legalisation of medicinal cannabis in 2018, following high-profile cases advocating for its use, the landscape has evolved but remains contentious. While the NHS prescribes a limited number of licensed cannabis-based medicinal products (CBMPs) for specific conditions such as severe epilepsy and multiple sclerosis, private clinics have proliferated, often prescribing unlicensed products.
Data from the Care Quality Commission indicates that a large proportion of privately prescribed cannabis products are unregulated, raising questions about their safety. In 2024, there were over 659,000 unlicensed cannabis prescriptions issued privately, a stark increase from the previous year. Yet, the evidence supporting cannabis as a treatment for mental health issues remains scarce, with experts urging caution in its use.
Why it Matters
The tragic death of Oliver Robinson underscores the urgent need for reform in the regulatory framework governing private cannabis clinics. As the demand for alternative treatments grows, it is imperative that safeguards are put in place to protect vulnerable individuals from potentially harmful prescriptions. The proposed changes under “Oliver’s Law” aim to ensure that the mental health of patients is prioritised over commercial interests, establishing a more responsible and evidence-based approach to medicinal cannabis in the UK. This case may serve as a pivotal moment in shaping future policies, highlighting the crucial balance between patient autonomy and safety in mental health treatment.
